Skip to main content
      RT @drdavidliew: I thought pirfenidone was just an anti-fibrotic - the spectrum of its MOA is actually fascinating

      @Eri

      David Liew drdavidliew

      3 years 2 months ago
      I thought pirfenidone was just an anti-fibrotic - the spectrum of its MOA is actually fascinating @ErinWilfongMD #ACR21 Antifibrotics session, chaired by @JuliePaikMD @RheumNow https://t.co/oMZOtfAUq0
      RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All

      Dr. John Cush RheumNow

      3 years 2 months ago
      RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its faculty.
      RT @RichardPAConway: DCVAS testing results in GCA. @davidliew @philipcrobinson are you guys essentially not imaging anyo

      Richard Conway RichardPAConway

      3 years 2 months ago
      DCVAS testing results in GCA. @davidliew @philipcrobinson are you guys essentially not imaging anyone in anyway? What's going on? #ACR21 @RheumNow https://t.co/IMr5ee2Iea
      RT @uptoTate: Billing and coding expert, Jean Acevedo shares the three URLs that you need to best understand the updated

      Dr. Rachel Tate uptoTate

      3 years 2 months ago
      Billing and coding expert, Jean Acevedo shares the three URLs that you need to best understand the updated 2021 EM coding! #ACR21 @RheumNow #RheumNow https://t.co/3HbDuZP8gC
      RT @bella_mehta: Pulmonary Arterial Hypertension in #AOSD
      Rare but severe complication - life threatening
      French study

      Bella Mehta bella_mehta

      3 years 2 months ago
      Pulmonary Arterial Hypertension in #AOSD Rare but severe complication - life threatening French study of 13 pts - network dataset. ALL FEMALES! Age 32, mean f/u 34 mths, 5 pts (38.5%) DIED @RheumNow #ACRBest abst#1100 https://t.co/5LIzHagesP
      Towards better assessment and management of multimorbidity by Dr. Mrinalini Dey ( @DrMiniDey ) #ACR21

      https://t.co/7DP

      Dr. John Cush RheumNow

      3 years 2 months ago
      Towards better assessment and management of multimorbidity by Dr. Mrinalini Dey ( @DrMiniDey ) #ACR21 https://t.co/7DPGsVB6bG https://t.co/F57k44AWZ4
      RT @MeralElRamahiMD: Knowledge Bowl at #ACR21

      ⭐️Approximately half of patients with IIM who develop pneumomediastin

      Meral K. El Ramahi, MD MeralElRamahiMD

      3 years 2 months ago
      Knowledge Bowl at #ACR21 ⭐️Approximately half of patients with IIM who develop pneumomediastinum have this subtype of dermatomyositis. ➡️Amyopathic (MDA5) dermatomyositis @RheumNow
      RT @MeralElRamahiMD: Knowledge Bowl at #ACR21

      ⭐️In a suspected PAN case, you order a peripheral smear to look for t

      Meral K. El Ramahi, MD MeralElRamahiMD

      3 years 2 months ago
      Knowledge Bowl at #ACR21 ⭐️In a suspected PAN case, you order a peripheral smear to look for this potential etiology, ➡️Hairy cells @RheumNow
      RT @RichardPAConway: JAK-pot registry-based study. Following JAKi failure should you switch mode of action or go to seco

      Richard Conway RichardPAConway

      3 years 2 months ago
      JAK-pot registry-based study. Following JAKi failure should you switch mode of action or go to second JAKi? Both seem equally effective in terms of drug retention. Didn't matter if switch for efficacy or adverse event. Abstr#1442 #ACR21 @RheumNow https://t.co/QEBB3flArC
      ×